CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Onyx Biotec Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Onyx Biotec Ltd
SCO 70, Level 2, Sector - 30 C
Phone: +91 1722656384p:+91 1722656384 CHANDIGARH, 160030  India Ticker: ONYXONYX
Business Summary
Onyx Biotec Ltd. is a pharmaceutical company engaged in the manufacture, sale, and distribution of generic and proprietary pharmaceutical products. It develops, manufactures and distributes generic and branded pharmaceutical products in various forms, like water for injection (WFI), dry powder injections, and dry powder syrup. WFI is a sterile preparation of water, which is supplied only in single-dose containers, indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection. Its dry powder injections include Ceftriaxone and Sulbactam for Injection, Cefazoline Sodium for Injection, and Cefepime and Tazobactam for Injection, among others. Its dry powder syrups include Cefpodoxime Proxetil, Cefuroxime Axetil, and others. Its core business is focused on providing end-to-end product development and manufacturing solutions to its clients. Its services also include preparation and filing of regulatory dossiers in the Indian and global markets.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20243/31/2024-----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
2836 Biological products, except diagnostic substances
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Whole Time Director, Chief Executive Officer, Chief Financial Officer HarshMahajan 37 7/23/2024 11/1/2022
Compliance Officer, Company Secretary HarshJhunjhunwala 36 7/23/2024 7/23/2024
Managing Director, Executive Director SanjayJain 62 7/23/2024 5/27/2008
6 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 18,132,200 (As of 3/31/2024)
Stock Exchange: NSE


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 22, 2024